Jacob A. Frenkel - Apr 6, 2022 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Role
Director
Signature
/s/ Jacob A. Frenkel
Stock symbol
BCLI
Transactions as of
Apr 6, 2022
Transactions value $
$0
Form type
4
Date filed
4/8/2022, 04:30 PM
Previous filing
Dec 10, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCLI Stock Option (right to buy) Award $0 +50K $0.00 50K Apr 6, 2022 Common Stock 50K $0.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, this option shall vest and become exercisable in 12 consecutive, equal monthly installments commencing on May 6, 2022 until fully vested and exercisable on the 12 month anniversary of April 6, 2022, provided that the Reporting Person remains a member of the Board of Directors of the Issuer on each vesting date.